These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2149 related articles for article (PubMed ID: 17284714)

  • 1. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
    Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
    J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
    Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
    J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
    Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
    J Clin Oncol; 2005 Jun; 23(18):4179-91. PubMed ID: 15961765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Warren JL; Brown ML
    J Natl Cancer Inst; 2007 Jul; 99(13):1050; author reply 1051-2. PubMed ID: 17596580
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Clavarezza M; Del Mastro L; Pronzato P; Bruzzi P; Venturini M
    J Natl Cancer Inst; 2007 Jul; 99(13):1050-1; author reply 1051-2. PubMed ID: 17596581
    [No Abstract]   [Full Text] [Related]  

  • 9. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
    Calip GS; Malmgren JA; Lee WJ; Schwartz SM; Kaplan HG
    Breast Cancer Res Treat; 2015 Nov; 154(1):133-43. PubMed ID: 26450505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer.
    Hershman DL; Buono D; McBride RB; Tsai WY; Joseph KA; Grann VR; Jacobson JS
    J Natl Cancer Inst; 2008 Feb; 100(3):199-206. PubMed ID: 18230795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy.
    Baxter NN; Durham SB; Phillips KA; Habermann EB; Virning BA
    J Am Geriatr Soc; 2009 Mar; 57(3):403-11. PubMed ID: 19278395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of radiation therapy for older women with early breast cancer.
    Smith BD; Gross CP; Smith GL; Galusha DH; Bekelman JE; Haffty BG
    J Natl Cancer Inst; 2006 May; 98(10):681-90. PubMed ID: 16705122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women.
    Hershman DL; Wang X; McBride R; Jacobson JS; Grann VR; Neugut AI
    Breast Cancer Res Treat; 2006 Oct; 99(3):313-21. PubMed ID: 16583264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy?
    Touw IP; Bontenbal M
    J Natl Cancer Inst; 2007 Feb; 99(3):183-6. PubMed ID: 17284707
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
    J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.
    Smith RE; Bryant J; DeCillis A; Anderson S;
    J Clin Oncol; 2003 Apr; 21(7):1195-204. PubMed ID: 12663705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 108.